NCT00747474 2019-11-18
Phase I Study of Intravenous LipotecanĀ® (TLC388 HCl for Injection) in Patients With Advanced Solid Tumors
Taiwan Liposome Company
Phase 1 Completed
Clinical Trials
5 trialsNCT02457273 2019-04-03
Phase II Study to Evaluate the Efficacy and Safety of TLC388 for Differentiated Neuroendocrine Carcinomas Patients
National Health Research Institutes, Taiwan
Phase 2 Completed
NCT02267213 2019-02-26
Efficacy and Safety Study of TLC388 to Advanced Hepatocellular Carcinoma
Taiwan Liposome Company
Phase 2 Terminated
NCT03035006 2018-11-06
Lipotecan Based Concurrent Chemoradiotherapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis
Taiwan Liposome Company
Phase 1/2 Terminated
NCT01425996 2018-08-21
A Dose-escalation Study of LipotecanĀ® Plus Radiotherapy in Locally Advanced Hepatocellular Carcinoma
Taiwan Liposome Company
Phase 1/2 Terminated